Test Your Knowledge Issue 342

Now that your patients are over their fear of activity, Sheri Colberg, Ph.D., FACSM helps you Choose Planned Activities-Strength and Flexibility for your patients, and how you can get your patients to do them.

That diabetes is fast becoming the epidemic of the 21st century which, now affects a shocking 246 million people worldwide, and is expected to affect over 380 million by 2025 if no action is taken.

The first big target for embryonic stem cell research in Australia will be a cure for diabetes, with a top researcher predicting major progress within four years.

In the PREDICTIVE Study in a subgroup of 2377 type 2’s not on insulin prior, (82%) achieved these benefits with once daily dosing of Levemir®.

Researchers in the December issue of Diabetes Care, found that the use of oral steroids can be a precipitating factor in some cases of new-onset diabetes

Drinking four or more cups of coffee a day could cut the risk of developing type-2 diabetes by over 23 per cent, say American and Finnish researchers.

Hopes for a vaccine to guard against juvenile diabetes have been boosted with the launch of a ground-breaking clinical trial in Melbourne.

Initial treatment with rosiglitazone slowed the progression to monotherapy failure more effectively than either metformin or glyburide.

Which treatment therapy was more effective?

The obesity epidemic is leading more people to develop type 1 and type 2 disease.

Department of Health of NY City, shows Trans Fats the Door, after voting unanimously to ban the substance from the city’s restaurants.

Drinking a protein hydrolysate/leucine beverage with meals reduces the prevalence of hyperglycemia in patients with type 2 diabetes, according to a new report.

Only 45% women in the cohort underwent postpartum glucose testing, as recommended.

New study results show patients with an HbA1c level of at least 8.5 when they started taking Acomplia saw their their blood sugar level decrease 1.9 points compared to 0.7 points in patients on a placebo.

Data Support JANUMET™, an Investigational Combination Therapy of Sitagliptin Phosphate Plus Metformin for Type 2 Diabetes

Skin autofluorescence, as a measure of the accumulation of advanced glycation end products (AGEs) in tissue, may serve as an indicator of vascular damage in patients with type 2 diabetes, according to a new report.